Aspirin Is Associated With Improved Venous Thromboembolism Prophylaxis Compared With Anticoagulants After Total Hip Arthroplasty in Patients Who Have Prior Hematologic Malignancy.
文献摘要
Background Patients who have prior hematologic malignancies undergoing total hip arthroplasty (THA) have elevated venous thromboembolism (VTE) risk. Although guidelines favor low-molecular weight heparin or direct oral anticoagulants in high-risk patients, these agents may increase bleeding and wound complications. Evidence supporting aspirin in this population remains limited. Methods A national administrative database identified patients diagnosed with a hematologic malignancy and underwent THA between 2010 and 2023. Patients were stratified by postoperative VTE prophylaxis. After propensity score matching, 1,043 patients who received aspirin were matched to 1,484 patients who received nonaspirin anticoagulation on demographics and comorbidities. The primary outcome was 90-day VTE. The secondary outcomes included postoperative complications, readmissions, and mortalities. Subgroup analyses evaluated malignancy-to-THA timing and anticoagulant classes. Results At 90 days, aspirin was associated with lower deep vein thrombosis rates compared with nonaspirin prophylaxis (0.3 versus 1.1%; odds ratio [OR] 0.25 [0.07 to 0.85]; P = 0.03). There were no differences in pulmonary embolism or mortality. Aspirin was associated with fewer emergency department visits (OR 0.62 [0.48 to 0.80]; P Conclusions Aspirin prophylaxis after THA in patients who have prior hematologic malignancy was associated with improved VTE prevention compared with anticoagulants and fewer postoperative complications, supporting its use as a safe option in patients who have recent or remote hematological malignancies. Level of evidence III (Retrospective Cohort Study).